Rituximab and tocilizumab appear to have better efficacy in reducing neuromyelitis optica spectrum disorder (NMOSD) relapses than other immunosuppressant agents such as azathioprine, according to a recently published study in the Journal of Neurology. NMOSD follows a recurrent course in which each relapse tends to be more severe than the last, eventually leading to debilitating neurological…
Neuromyelitis optica spectrum disorder (NMOSD) appears to be associated with worse outcomes than myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), regardless of ethnicity, in the Latin American population, according to a recently published study in Multiple Sclerosis and Related Disorders. Although there are different pathological mechanisms involved in NMOSD and MOGAD, the former being astrocytopathy and…
A 7-day delay in methylprednisolone administration in patients with optic neuritis due to neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), or double-seronegative optic neuritis (DN-ON) significantly decreases the odds of gaining visual recovery, according to a recently published study in Vision. Optic neuritis can be caused by several diseases, including NMOSD, MS, and DN-ON.…
Patients with neuromyelitis optica spectrum disorder (NMOSD) that have an onset of the condition at a younger age, polysystem involvement in the first attack, and increased or unchanged titer of aquaporin-4 (AQP4-IgG) are most likely to experience relapse under treatment with immunosuppressants, a study found. The study suggested a higher efficacy treatment than immunosuppressants might…
Patients with neuromyelitis optica spectrum disorder (NMOSD) are commonly misdiagnosed, leading to delays in treatment initiation, according to an international study published in Neurology and Therapy. The study, which analyzed clinical records from the United States, Germany, Italy, Brazil, South Korea, and China, found that roughly 25% of aquaporin-4 (AQP4) immunoglobulin G (IgG)-seropositive adults with…
Inebilizumab-cdon (Uplizna®) could be effective for treating neuromyelitis optica spectrum disorder (NMOSD) without carrying major consequences regarding immune function against coronavirus disease 2019 (COVID-19), according to a news release from Horizon Therapeutics. “Patients treated with Uplizna appear to not be more susceptible to COVID-19 infections or to develop waning immunity from prior vaccinations due to…
Using 1 gram rituximab as maintenance therapy for inflammatory neurologic conditions such as neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) appears to be effective maintenance therapy. In contrast, 2 grams seem excessive, according to a recently published study in Multiple Sclerosis and Related Disorders. Several studies have widely established the efficacy of rituximab…
More than half (52%) of neuromyelitis optica spectrum disorders (NMOSD) relapse events incurred out-of-pocket costs to patients, found a new cross-sectional survey-based study published in the journal Multiple Sclerosis and Related Disorders. The average cost per event was $3326 to the patients. More than a quarter (26%) of relapse events also led to indirect costs…
The risk of developing neuromyelitis optica spectrum disorder (NMOSD) is 8 times greater in people of East Asian and Black descent compared to White people, according to a case-control study conducted in Canada and published in the Multiple Sclerosis Journal. The risk of the disease is also higher in other nonWhite participants, those born outside…
Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience neuropsychological impairment, according to a study published in the Multiple Sclerosis Journal. The results of the prospective multicenter study called CogniNMO-Study showed that patients with NMOSD had impaired visual processing speed and semantic fluency. Testing revealed significantly lower scores on the Symbol Digit Modalities Test (SDMT;…
Please login or register first to view this content.
